AATB Names C5 Biomedical CEO Tim Maye Among 50 Honorees Marking the Association's 50th Anniversary
AATB Names C5 Biomedical CEO Tim Maye Among 50 Honorees Marking the Association's 50th Anniversary
PR Newswire
BOCA RATON, Fla., Oct. 6, 2026
Maye, CTBS, has spent nearly three decades in the field, including six years chairing AATB's Standards Committee
BOCA RATON, Fla., Oct. 6, 2026 /PRNewswire/ -- C5 Biomedical LLC, an FDA-registered, AATB-accredited manufacturer of amniotic membrane allografts, today announced that its Chief Executive Officer, Tim Maye, CTBS, will be honored tonight in San Francisco as one of the "50 at 50" honorees at the 50th Anniversary Celebration of the Association for Advancing Tissue and Biologics (AATB).
The 50 at 50 is a one-time honor recognizing 50 individuals who have shaped AATB and the broader tissue and biologics field.
Maye has spent 28 years in tissue banking and biologics and has held his Certified Tissue Bank Specialist (CTBS) credential since 1999. He chaired AATB's Standards Committee for six years and founded C5 Biomedical in 2021.
C5 Biomedical earned AATB accreditation in November 2025 under standards Maye helped write.
"This recognition belongs to everyone who's helped raise the bar in tissue banking over the last three decades. I've had the privilege of helping write some of the standards this industry runs on today, and I'm not finished. I still sit on that committee, and there's more work ahead I want to see through," said Tim Maye, CTBS, CEO of C5 Biomedical.
"Tim chaired the AATB Standards Committee for six years, during which time I had the opportunity to be the liaison to this extremely important and impactful committee. The foundation of the Association has always been the establishment and refinement of our Standards for Tissue Banking, and Tim was able to continue that legacy without missing a beat. Tim brought cohesion and calm leadership to his role, completely voluntary, that allowed members of the committee to discuss and debate the issues to achieve best outcomes," said Beverly Bliss, MBA, CTBS, former AATB Vice President of Accreditation and Standards.
The celebration is part of AATB Congress 26. The full list of honorees is on AATB's website (https://www.aatb.org/news/aatb-announces-its-50-50-honorees).
About C5 Biomedical LLC
C5 Biomedical is an FDA-registered, AATB-accredited manufacturer of amniotic membrane allografts for use across wound care, burn, ocular, spine, orthopedic and other surgical applications. Its product lines include AéroGuard™, NéoGuard™, xPatch™ and iPatch™. C5 Biomedical also manufactures private-label allografts for distributors. For more information, contact info@c5biomedical.com.
About AATB
The Association for Advancing Tissue and Biologics (AATB), formerly the American Association of Tissue Banks, is the standard-setting body for the safety and use of donated human tissue.
Media Contact:
Stephen Maye
Chief Revenue Officer
C5 Biomedical LLC
stephen@c5biomedical.com
703-371-8392
SOURCE C5 Biomedical LLC
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
Why This Vanguard ETF Is One of the Best
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
United States